CYSLTR2 L129Q

CI-VAR-00002226Explore in graph →CIViC 3660

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
CYSLTR2 L129Q	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID10010 Analysis of genomic data from 136 uveal melanoma samples identified a hotspot mutation in CYSLTR2 that is mutually exclusive with the more common GNAQ and GNA11 mutations. CYSLTR2 L129Q expression in … (full text at CIViC) PMID 27089179 · Moore et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.